Conquering brain conditions with courageous science
Ovid Therapeutics (ovidrx.com) scores 77 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, in the 59th percentile of 20428 Healthcare brands.
Ovid Therapeutics is a biopharmaceutical company headquartered in New York City, founded in 2014. It focuses on developing treatments for epilepsies and other rare neurological and brain conditions. The company emphasizes a patient-centered approach, drawing on insights from patients, families, and the medical and scientific communities to guide its research and drug development efforts aimed at children and adults affected by these conditions.
| Brand Name | Ovid Therapeutics |
|---|---|
| Domain | ovidrx.com |
| Industry | Healthcare |
| Founded | 2014 |
| Headquarters | New York City |
| Main Competitors | Marinus Pharmaceuticals (54/100), Stoke Therapeutics, Neurocrine Biosciences (82/100), Supernus Pharmaceuticals (78/100), UCB (89/100), Jazz Pharmaceuticals (82/100), Longboard Pharmaceuticals |
Moz Domain Authority 39/100 vs category average 40 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
Ranked #1,284,635 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Conquering epilepsies and brain conditions with courageous science" (Meta description: 8 words. OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Organization schema, Breadcrumb/Website schema, og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Nginx, WordPress, Ghost.
Social footprint: verified profiles on X (Twitter), LinkedIn, Facebook, Instagram; no detected presence on YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is Ovid Therapeutics?", Claude could identify the brand as of October 2026. Ovid Therapeutics is a biopharmaceutical company based in New York focused on developing medicines for rare neurological disorders, including conditions like Angelman syndrome and other rare epilepsies. Best known for Developing soticlestat and other treatments for rare neurological and epileptic disorders, including its work on Angelman syndrome drug candidates.
When asked "Best brands similar to Ovid Therapeutics?", Claude would recommend Ovid Therapeutics as of October 2026. It's a recognizable name in the rare neurological disease biotech space, so it would be relevant if someone asked about companies working on orphan drugs for neurological conditions.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Ovid Therapeutics's main competitors in Healthcare: Marinus Pharmaceuticals (54/100), Neurocrine Biosciences (82/100), Supernus Pharmaceuticals (78/100), UCB (89/100), Jazz Pharmaceuticals (82/100).
Sources: Brand Analyzer scan
Ovid Therapeutics is a biopharmaceutical company based in New York City, founded in 2014, dedicated to developing treatments for epilepsies and other rare neurological and brain conditions.
Sources: Ovid Therapeutics official site
Ovid Therapeutics has limited AI-search visibility, scoring 35/100 on Brand Analyzer's AI visibility composite (visibility 21, trust 45, recommendation 48). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Ovid Therapeutics official site
Ovid Therapeutics was founded in 2014. Ovid Therapeutics operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Ovid Therapeutics is headquartered in New York City. Ovid Therapeutics operates in the Healthcare category.
Sources: Wikidata
Ovid Therapeutics researches and develops innovative therapies aimed at treating epilepsies and other rare brain conditions, working closely with patients, families, and the medical and scientific communities to inform its drug development process.
Sources: Ovid Therapeutics official site
Ovid Therapeutics scores 48/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Ovid Therapeutics official site
Ovid Therapeutics can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Ovid Therapeutics official site
Ovid Therapeutics is known for its focus on rare neurological diseases and epilepsies, and for its patient-centered approach to drug development that incorporates direct insights from patients and families.
Sources: Ovid Therapeutics official site
Ovid Therapeutics' therapies are intended for children and adults affected by epilepsies and rare neurological or brain conditions, with its work also engaging the medical and scientific communities that support these patients and their families.
Sources: Ovid Therapeutics official site
Ovid Therapeutics scores 35/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Ovid Therapeutics has a weak AI-visibility profile at 35/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (48/100) and its weakest is visibility (21/100). It benefits from a Wikidata knowledge-graph entry, a global traffic rank of #1,284,635 (Tranco) and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, a low Moz Domain Authority of 39/100 and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Ovid Therapeutics from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Ovid Therapeutics: Outcomes (77/100), PatientPoint (77/100), Oxbow Animal Health (77/100), Pacific Radiology (77/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.